Tumor Microenvironment-Responsive Hydrogen-Generating Zn-Doped ReZIF-8 Nanoplatform for Enhanced Tumor Suppression.
Kexin Qin, Zitong Zheng, Yuemin Zhou, Xingcan Shen, Ruikang Tang, Xiaoyu Wang · Advanced healthcare materials · 2026
Research-use notice
Independent study record
Each H2HUBB study page organizes source-linked research details for educational use. Interpretation should remain proportional to the study design, population, controls, and limitations.
H2HUBB TAKEAWAY
In mice, to address these limitations, a partially reduced zinc-doped zeolitic imidazolate framework-8 (ReZIF-8) is developed, functioning as a dual-functional nanoplatform for both intracellular hydrogen generation and controlled Zn(II) ions (Zn2+) overload. These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
What the Findings Mean
H2HUBB reviewed how molecular hydrogen affected the outcomes measured in mice. To address these limitations, a partially reduced zinc-doped zeolitic imidazolate framework-8 (ReZIF-8) is developed, functioning as a dual-functional nanoplatform for both intracellular hydrogen generation and controlled Zn(II) ions (Zn2+) overload.
What the Researchers Studied
The researchers studied mice. The study used a preclinical animal experiment. The comparison condition was control condition or baseline measurements.
What Effects Did Molecular Hydrogen Have?
Hydrogen-based tumor therapy demonstrates therapeutic potential, while the efficacy remains limited by insufficient intracellular hydrogen generation, poorly controlled release kinetics, and inadequate immune response potentiation. To address these limitations, a partially reduced zinc-doped zeolitic imidazolate framework-8 (ReZIF-8) is developed, functioning as a dual-functional nanoplatform for both intracellular hydrogen generation and controlled Zn(II) ions (Zn2+) overload.
Why These Findings Matter
These preclinical findings add evidence supporting molecular hydrogen's therapeutic potential within the outcomes and biological pathways measured in this model.
How Strong Is This Evidence?
This is preclinical animal evidence from a preclinical animal experiment. It is most informative for the disease model, mechanisms, biomarkers, and outcomes directly measured in the study.
Technical Study Details
H2HUBB classifies this publication as animal study with preclinical animal evidence. The research population or model was mice. The study used a preclinical animal experiment.
Limitations and Safety
Reported limitations: Hydrogen-based tumor therapy demonstrates therapeutic potential, while the efficacy remains limited by insufficient intracellular hydrogen generation, poorly controlled release kinetics, and inadequate immune response potentiation. To address these limitations, a partially reduced zinc-doped zeolitic imidazolate framework-8 (ReZIF-8) is developed, functioning as a dual-functional nanoplatform for both intracellular hydrogen generation and controlled Zn(II) ions (Zn2+) overload.
Original Study and H2HUBB Research Context
H2HUBB presents this source-grounded research record as one contribution to the broader molecular-hydrogen evidence base.